OCUL
Ocular Therapeutix, Inc.
NASDAQ · USHealthcareBiotechnology
$8.71-2.90%
Price as of Jul 20, 2026
OCUL financials
Ocular Therapeutix, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $51.8M | $63.7M | $58.4M | $51.5M |
| Cost of revenue | $6.6M | $5.6M | $5.3M | $4.5M |
| Gross profit | $45.2M | $58.1M | $53.2M | $47.0M |
| Operating expenses | $315.4M | $229.9M | $135.5M | $125.6M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M |
| EBITDA | -$249.8M | -$176.1M | -$66.4M | -$61.9M |
| Basic EPS | $-1.42 | $-1.22 | $-1.09 | $-1.04 |
| Diluted EPS | $-1.42 | $-1.22 | $-1.02 | $-0.97 |
| Balance sheet | ||||
| Cash & equivalents | $737.1M | $392.1M | $195.8M | $102.3M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M |
| Stockholders’ equity | $654.3M | $315.3M | $91.1M | $35.4M |
| Total debt | $79.8M | $75.8M | $83.4M | $64.3M |
| Net debt | -$657.3M | -$316.3M | -$112.4M | -$38.0M |
| Cash flow | ||||
| Operating cash flow | -$204.9M | -$134.7M | -$70.2M | -$59.6M |
| Capital expenditure | -$12.0M | -$1.3M | -$6.1M | -$3.7M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |